Clinical Trials Logo

Clinical Trial Summary

The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana [Delta-9-tetrahydracannabinol (THC)] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.


Clinical Trial Description

The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana [Delta-9-tetrahydracannabinol (THC)] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability. Marijuana plant material will be obtained from the National Institutes on Drug Abuse (NIDA). In clinical studies, oral synthetic THC reduced the severity of opioid withdrawal during opioid detoxification. Clinically, cannabinoid drugs like Marinol® (oral synthetic THC), Sativex ® (nabixomols), and Cesamet® (nabilone) are used to treat nausea and vomiting, common symptoms of opioid withdrawal. This study will investigate the ability of vaporized marijuana (V-MJ) (0.00, 12.5, and 25 mg: concentration= 11.7% THC + 0.04% CBD) to reduce the severity of opioid withdrawal precipitated by intranasal (IN) NLX (0.0 and 4.0 mg). This trial will recruit healthy participants with opioid use disorder (N=16, completers). Testing will begin following stabilization on oral morphine (120 mg/day), which will continue throughout the trial. During each testing session, a single V-MJ + naloxone dose combination will be assessed (in randomized order), with 48 hours between testing sessions. Laboratory testing sessions will consist of a modified naloxone challenge procedure, which quantifies the severity of naloxone-precipitated opioid withdrawal. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05114460
Study type Interventional
Source New York State Psychiatric Institute
Contact Freyon Perez, BA
Phone 646 774-6182
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03924505 - Preventing Opioid Overdose Mortality in the United States N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Recruiting NCT04317053 - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program Phase 3
Not yet recruiting NCT05123027 - Peer Intervention to Link Overdose Survivors to Treatment (PILOT) N/A
Not yet recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Active, not recruiting NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Suspended NCT04740099 - Surviving Opioid Overdose With Naloxone Education and Resuscitation Trial (SOONER) N/A
Recruiting NCT05072249 - European Cohort Study of the Effectiveness of Take Home Naloxone
Not yet recruiting NCT01622504 - Naloxone Nasal Spray Pharmacokinetic Study Phase 1
Active, not recruiting NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Completed NCT04713709 - A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Phase 1
Recruiting NCT05008523 - Opioids and Police Safety Study N/A
Completed NCT01788306 - Project OOPEN: Opioid Overdose Prevention, Education and Intervention Phase 4
Not yet recruiting NCT04589676 - Developing and Testing the Opioid Rapid Response System Phase 3
Recruiting NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Completed NCT04530591 - User Acceptability of a Device-Based Opioid Overdose Intervention
Recruiting NCT04984109 - Ultrasound-guided PENG Block in Total Hip Replacement N/A
Recruiting NCT03968237 - Measures to Improve Outcomes After an Opioid Overdose
Recruiting NCT04811014 - Young Houston Emergency Opioid Engagement System Phase 4
Not yet recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose Phase 4